Etuvetidigene Autotemcel: First Approval

Area of Science:

• Hematology
• Gene Therapy
• Immunology

Background:

• Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency.
• Current treatments include hematopoietic stem cell transplantation (HSCT), which requires a matched donor.
• Gene therapy offers a potential alternative for patients without a suitable donor.

Purpose of the Study:

• To summarize the development milestones of etuvetidigene autotemcel.
• To highlight its recent regulatory approvals for WAS treatment.

Main Methods:

• Autologous hematopoietic stem cell (HSC) gene therapy approach.
• Development by Fondazione Telethon.
• Regulatory review processes in the USA and EU.

Main Results:

• Etuvetidigene autotemcel (WASKYRA™) development milestones leading to regulatory approval.
• FDA approval in December 2025 for WAS patients aged 6 months and older.
• EMA approval in January 2026 for the same indication.

Conclusions:

• Etuvetidigene autotemcel represents a significant advancement in WAS treatment.
• The therapy provides a new option for patients ineligible for traditional HSCT.
• Successful development and approval mark a milestone in rare disease gene therapy.